Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio
Mandate

Vinge advises AstraZeneca on the sale of a pharmaceutical portfolio

June 04, 2007

Vinge is advising AstraZeneca on the sale of a large number of pharmaceuticals to Recip AB. The sale includes a portfolio of infection drugs for sale in Sweden, Norway, Denmark and Iceland. The annual sales of the 17 drugs included in the portfolio are SEK 240 million.

AstraZeneca is represented by partner Malin Leffler, assisted by Anna Berntsson and Claes Henriksson.

Related

Vinge has represented Anaqua, a portfolio company of Nordic Capital, in connection with the acquisition of Patrix

 Vinge has represented Anaqua, Inc., a portfolio company of Nordic Capital, in connection with the acquisition of Patrix Aktiebolag, provider of IP management software and services. The acquisition is a strategic addition to Anaqua's platform, further expanding its European presence.
April 30, 2026

Vinge advises parts of the consortium in connection with the public takeover offer for Cint

 The public takeover offer was announced by a consortium consisting of Triton Fund 6, Bolero, Patrick Comer and Brett Schnittlich. The offer values all shares in Cint at approximately SEK 1,989 million. The shares in Cint are listed on Nasdaq Stockholm, Mid Cap.
April 27, 2026

Nordea and SEB enters into a SEK 2,000,000,000 credit facility agreement

 On 22 April 2026, Nordea and SEB entered into a credit facility agreement in the aggregate amount of SEK 2,000,000,000 (with an accordion option for an additional SEK 400,000,000) with Humble Group AB (publ).
April 27, 2026